Press Releases

London, UK, 11 June 2018: BTG plc (LSE: BTG), the global healthcare company, today announces the start of ELEVATE: A randomizEd ControlLed Study of PnEumRx™ Endobronchial Coil System (Coils) Versus Standard of Care Medical MAnagement in the Treatment of Subjects with Severe Emphysema.

London, UK, 5 December 2016: BTG plc (LSE: BTG), the global specialist healthcare company, today announces the inclusion of treatment with lung coils in guidelines for the management of chronic obstructive pulmonary disease (COPD) published by the Global Initiative for Chronic Obstructive Lung Disease (GOLD). At the same time, the French Ministry of Health has published its positive recommendations regarding PneumRx® Coils on its website.

Dr. Joseph Cicenia from the Cleveland Clinic, comments on the recent REVOLENS publication in the Journal of American Medical Association.

Professors Gaetan Deslee and Charles-Hugo Marquette, Primary Investigators of the REVOLENS Study Group, “Lung Volume Reduction Coil Treatment vs. Usual Care in Patients with Severe Emphysema: The REVOLENS Randomized Clinical Trial” is published in the JAMA 2016;315(2):175-184.Doi:10.1001/jama.2015.17821.

Study meets all primary and secondary endpoints London, UK, 14 December : BTG plc (LSE: BTG), the specialist healthcare company, today announces the successful outcome of the RENEW study, the pivotal US randomised controlled clinical trial comparing the safety and efficacy of the PneumRx^® endobronchial coil implant (EBCI) with a medical therapy control group in patients with homogeneous and/or heterogeneous severe emphysema.

PneumRx, Inc. (www.pneumrx.com), a leader in the field of interventional pulmonology, today announced that it has signed an agreement to be acquired by BTG Plc (LSE:BTG) in a deal worth up to $475 million, based on an initial consideration of $230 million and up to $245 million in performance-related milestone payments. Based in London, BTG is an international specialist healthcare company that is active in interventional medicine and specialty pharmaceuticals. Their current interventional portfolio includes site-specific treatments for severe blood clots including pulmonary embolisms, liver tumors, and varicose veins. These therapies are differentiated, minimally invasive, and marketed to specialist physician groups.